Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Roche Holding AG RHHBY OTC

Other OTC • Healthcare • Drug Manufacturers - General • CH • USD

SharesGrow Score
68/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$48.00
-5.9%

Roche Holding AG (RHHBY) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $51.02. It has a SharesGrow Score of 68/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is RHHBY = $48 (-5.9% upside).

Financials: revenue is $63.4B, +0.1%/yr average growth. Net income is $12.9B, growing at +6.7%/yr. Net profit margin is 20.3% (strong). Gross margin is 73.7% (+3.5 pp trend).

Balance sheet: total debt is $31.7B against $33.8B equity (Debt-to-Equity (D/E) ratio 0.94, moderate). Current ratio is 1.38 (adequate). Debt-to-assets is 31.4%. Total assets: $100.8B.

Analyst outlook: 3 / 9 analysts rate RHHBY as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 46/100 (Partial), Growth 55/100 (Partial), Past 100/100 (Pass), Health 67/100 (Partial), Moat 94/100 (Pass), Future 26/100 (Fail), Income 85/100 (Pass).

$48.00
▼ 5.92% Downside
Average Price Target
The 12-month price target for Roche Holding AG is $48.00.

RHHBY SharesGrow Score Overview

68/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 46/100
Valuation — P/E, PEG, Forward PEG
GROWTH 55/100
Financials — average growth
PAST 100/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 94/100
Gross margin is + market cap
FUTURE 26/100
Analyst outlook — as buy
INCOME 85/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RHHBY

~
VALUE Partial
46/100
RHHBY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $48, implying -5.9% from the current price $51. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
55/100
RHHBY: +0.1%/yr revenue is, +6.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✓
PAST Pass
100/100
RHHBY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet RHHBY: Debt-to-Equity (D/E) ratio 0.94 (moderate), Current ratio is 1.38 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
94/100
RHHBY: Gross margin is 73.7% (+3.5 pp trend), $329B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 94/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
26/100
Analyst outlook: 3 / 9 analysts rate RHHBY as buy (33%). Analyst consensus target is $48 (-5.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✓
INCOME Pass
85/100
RHHBY: Net profit margin is 20.3%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range34.75-60.85
Volume756.46K
Avg Volume (30D)2.56M
Market Cap$328.61B
Beta (1Y)0.33
Dividend Yield$1.0007
Share Statistics
EPS (TTM)2.02
Shares Outstanding$6.42B
IPO Date2003-08-20
Employees103,249
CEOThomas Schinecker
Financial Highlights & Ratios
Revenue (TTM)$63.36B
Gross Profit$46.71B
EBITDA$21.71B
Net Income$12.88B
Operating Income$18.48B
Total Cash$15.49B
Total Debt$31.67B
Net Debt$26.08B
Total Assets$100.82B
Price / Earnings (P/E)25.3
Price / Sales (P/S)5.19
Analyst Forecast
1Y Price Target$48.00
Target High$48.00
Target Low$48.00
Upside-5.9%
Rating ConsensusHold
Analysts Covering9
Buy 33% Hold 56% Sell 11%
Company Info
CountryCH
ExchangeOther OTC
CurrencyUSD
ISINUS7711951043

Price Chart

Track all markets on TradingView
RHHBY
Roche Holding AG ↗  ·  Other OTC
Healthcare • Drug Manufacturers - General
34.75 52WK RANGE 60.85

People Also View

AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
 NVS
NVS
Novartis AG
$153.38
-0.71%
 GILD
GILD
Gilead Sciences, Inc.
$140.45
+1.02%
 GSK
GSK
GSK plc
$59.18
+0.41%
 BMY
BMY
Bristol-Myers Squibb Company
$58.08
+0.03%
 SNY
SNY
Sanofi
$47.64
+1.45%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message